JP2017501129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501129A5 JP2017501129A5 JP2016533150A JP2016533150A JP2017501129A5 JP 2017501129 A5 JP2017501129 A5 JP 2017501129A5 JP 2016533150 A JP2016533150 A JP 2016533150A JP 2016533150 A JP2016533150 A JP 2016533150A JP 2017501129 A5 JP2017501129 A5 JP 2017501129A5
- Authority
- JP
- Japan
- Prior art keywords
- cell receptor
- modified
- amino acid
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008874 T cell receptors Proteins 0.000 claims description 59
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 59
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 108010002687 Survivin Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 102000000763 Survivin Human genes 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 102200124874 rs28928896 Human genes 0.000 claims description 2
- 102200124875 rs59151893 Human genes 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907887P | 2013-11-22 | 2013-11-22 | |
| US61/907,887 | 2013-11-22 | ||
| PCT/US2014/066892 WO2015077607A1 (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501129A JP2017501129A (ja) | 2017-01-12 |
| JP2017501129A5 true JP2017501129A5 (enExample) | 2017-12-28 |
| JP6476182B2 JP6476182B2 (ja) | 2019-02-27 |
Family
ID=53180203
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533150A Active JP6476182B2 (ja) | 2013-11-22 | 2014-11-21 | 改変された高親和性ヒトｔ細胞受容体 |
| JP2016533163A Expired - Fee Related JP6697386B2 (ja) | 2013-11-22 | 2014-11-21 | 改変された高親和性ヒトｔ細胞受容体 |
| JP2019190139A Expired - Fee Related JP6970724B2 (ja) | 2013-11-22 | 2019-10-17 | 改変された高親和性ヒトｔ細胞受容体 |
| JP2021178468A Pending JP2022023196A (ja) | 2013-11-22 | 2021-11-01 | 改変された高親和性ヒトｔ細胞受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533163A Expired - Fee Related JP6697386B2 (ja) | 2013-11-22 | 2014-11-21 | 改変された高親和性ヒトｔ細胞受容体 |
| JP2019190139A Expired - Fee Related JP6970724B2 (ja) | 2013-11-22 | 2019-10-17 | 改変された高親和性ヒトｔ細胞受容体 |
| JP2021178468A Pending JP2022023196A (ja) | 2013-11-22 | 2021-11-01 | 改変された高親和性ヒトｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10023625B2 (enExample) |
| EP (2) | EP3071594A4 (enExample) |
| JP (4) | JP6476182B2 (enExample) |
| KR (2) | KR20160085345A (enExample) |
| CN (2) | CN105873945B (enExample) |
| AU (4) | AU2014352834B2 (enExample) |
| BR (1) | BR112016011567A2 (enExample) |
| CA (2) | CA2930847A1 (enExample) |
| DK (1) | DK3071593T3 (enExample) |
| ES (1) | ES2729406T3 (enExample) |
| IL (2) | IL245467B (enExample) |
| MX (3) | MX371202B (enExample) |
| PL (1) | PL3071593T3 (enExample) |
| PT (1) | PT3071593T (enExample) |
| RU (2) | RU2729383C2 (enExample) |
| SA (1) | SA516371174B1 (enExample) |
| SG (2) | SG10201804335QA (enExample) |
| TR (1) | TR201908404T4 (enExample) |
| WO (2) | WO2015077607A1 (enExample) |
| ZA (2) | ZA201603116B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2542141T3 (es) | 2005-10-17 | 2015-07-31 | Sloan Kettering Institute For Cancer Research | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
| CA2645766A1 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性ｗｔ１ペプチド及びその使用方法 |
| EP2945647B1 (en) | 2013-01-15 | 2020-09-09 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| DK3071593T3 (da) | 2013-11-22 | 2019-06-11 | The Board Of Trustees Of The Univ Of Illionis | Modificerede humane t-celle-receptorer med høj affinitet |
| US20190169637A1 (en) * | 2015-09-22 | 2019-06-06 | Julius-Maximilians-Universität Würzburg | A method for high level and stable gene transfer in lymphocytes |
| AU2016329542C1 (en) * | 2015-10-01 | 2023-11-23 | Fondazione Centro San Raffaele | TCR and uses thereof |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| WO2018090057A1 (en) * | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
| BR112019018863A8 (pt) * | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
| ES3027565T3 (en) * | 2017-04-24 | 2025-06-16 | Ospedale San Raffaele Srl | Tcr and peptides |
| JP7181517B2 (ja) | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| EP3826626A4 (en) * | 2018-07-23 | 2022-07-06 | Magenta Therapeutics, Inc. | USE OF ANTI-CD137 ANTIBODY-DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| JP7611844B2 (ja) | 2019-03-11 | 2025-01-10 | フレッド ハッチンソン キャンサー センター | 高アビディティｗｔ１ｔ細胞受容体とその使用 |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| JP7737978B2 (ja) * | 2019-08-20 | 2025-09-11 | フレッド ハッチンソン キャンサー センター | Ｗｔ－１に特異的なｔ細胞免疫療法 |
| EP4103616A1 (en) * | 2020-02-12 | 2022-12-21 | AbbVie Inc. | Bispecific binding molecules |
| EP4142746A1 (en) | 2020-04-28 | 2023-03-08 | Achilles Therapeutics UK Limited | T cell therapy |
| CN112239495B (zh) * | 2020-10-29 | 2022-04-12 | 上海药明生物技术有限公司 | 稳定的tcr结构及应用 |
| US20220323500A1 (en) | 2021-04-09 | 2022-10-13 | Achilles Therapeutics Uk Limited | Cancer immunotherapy |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| CN117580946A (zh) | 2021-06-22 | 2024-02-20 | 阿基里斯治疗英国有限公司 | 用于产生抗原特异性t细胞的方法 |
| CN117957012A (zh) * | 2021-07-19 | 2024-04-30 | 得克萨斯州大学系统董事会 | 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法 |
| CN119220425A (zh) * | 2023-07-28 | 2024-12-31 | 佳吾益(北京)科技有限公司 | 发现mhc新抗原肽表位的工程化细胞 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4640561A (en) | 1985-11-15 | 1987-02-03 | Ford Motor Company | Flexible printed circuit connector |
| US5059413A (en) | 1988-04-18 | 1991-10-22 | Xoma Corporation | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5299253A (en) | 1992-04-10 | 1994-03-29 | Akzo N.V. | Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| DE69900468T2 (de) | 1998-05-19 | 2002-07-18 | Avidex Ltd | Löslicher t-zell rezeptor |
| WO2000023087A1 (en) | 1998-10-21 | 2000-04-27 | Sunol Molecular Corporation | Polyspecific binding molecules and uses thereof |
| WO2003020763A2 (en) | 2001-08-31 | 2003-03-13 | Avidex Limited | Soluble t cell receptor |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| JP4436319B2 (ja) | 2002-10-09 | 2010-03-24 | メディジーン リミテッド | 単鎖組換えｔ細胞レセプター |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| AU2005246073B2 (en) | 2004-05-19 | 2010-10-28 | Adaptimmune Limited | Method of improving T cell receptors |
| CA2566363C (en) | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| EP2352756B1 (en) * | 2008-11-24 | 2012-09-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | High affinity t cell receptor and use thereof |
| WO2010075417A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| AU2010210083C1 (en) | 2009-02-09 | 2015-11-26 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2011044186A1 (en) * | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| CN103097407A (zh) * | 2010-07-28 | 2013-05-08 | 英美偌科有限公司 | T细胞受体 |
| BR122020026648B1 (pt) | 2010-09-20 | 2021-12-07 | Biontech Cell & Gene Therapies Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| KR20150009556A (ko) * | 2012-05-03 | 2015-01-26 | 프레드 헛친슨 켄서 리서치 센터 | 증강된 친화성 t 세포 수용체 및 이의 제조 방법 |
| WO2014191465A1 (en) * | 2013-05-28 | 2014-12-04 | Møller Niels Iversen | Peptides derived from lawsonia intracellularis and their use in vaccination |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| DK3071593T3 (da) | 2013-11-22 | 2019-06-11 | The Board Of Trustees Of The Univ Of Illionis | Modificerede humane t-celle-receptorer med høj affinitet |
| US10538572B2 (en) | 2014-08-04 | 2020-01-21 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for WT-1 |
| CN110950964B (zh) * | 2018-09-26 | 2021-06-18 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 |
-
2014
- 2014-11-21 DK DK14863490.0T patent/DK3071593T3/da active
- 2014-11-21 JP JP2016533150A patent/JP6476182B2/ja active Active
- 2014-11-21 PT PT14863490T patent/PT3071593T/pt unknown
- 2014-11-21 RU RU2016124163A patent/RU2729383C2/ru active
- 2014-11-21 SG SG10201804335QA patent/SG10201804335QA/en unknown
- 2014-11-21 AU AU2014352834A patent/AU2014352834B2/en not_active Ceased
- 2014-11-21 CA CA2930847A patent/CA2930847A1/en not_active Abandoned
- 2014-11-21 TR TR2019/08404T patent/TR201908404T4/tr unknown
- 2014-11-21 US US15/037,476 patent/US10023625B2/en active Active
- 2014-11-21 CA CA2930852A patent/CA2930852C/en active Active
- 2014-11-21 EP EP14864079.0A patent/EP3071594A4/en active Pending
- 2014-11-21 MX MX2016006620A patent/MX371202B/es active IP Right Grant
- 2014-11-21 WO PCT/US2014/066892 patent/WO2015077607A1/en not_active Ceased
- 2014-11-21 BR BR112016011567A patent/BR112016011567A2/pt not_active Application Discontinuation
- 2014-11-21 EP EP14863490.0A patent/EP3071593B1/en active Active
- 2014-11-21 KR KR1020167016132A patent/KR20160085345A/ko not_active Ceased
- 2014-11-21 CN CN201480071620.2A patent/CN105873945B/zh active Active
- 2014-11-21 WO PCT/US2014/066903 patent/WO2015077615A1/en not_active Ceased
- 2014-11-21 CN CN201480071635.9A patent/CN105899530B/zh not_active Expired - Fee Related
- 2014-11-21 US US15/037,485 patent/US10344075B2/en active Active
- 2014-11-21 KR KR1020167016131A patent/KR102415259B1/ko active Active
- 2014-11-21 PL PL14863490T patent/PL3071593T3/pl unknown
- 2014-11-21 JP JP2016533163A patent/JP6697386B2/ja not_active Expired - Fee Related
- 2014-11-21 MX MX2016006625A patent/MX383471B/es unknown
- 2014-11-21 SG SG10201804330YA patent/SG10201804330YA/en unknown
- 2014-11-21 ES ES14863490T patent/ES2729406T3/es active Active
- 2014-11-21 RU RU2016124179A patent/RU2740648C2/ru active
- 2014-11-21 AU AU2014352826A patent/AU2014352826B2/en active Active
-
2016
- 2016-05-04 IL IL245467A patent/IL245467B/en not_active IP Right Cessation
- 2016-05-04 IL IL245468A patent/IL245468B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03116A patent/ZA201603116B/en unknown
- 2016-05-11 ZA ZA2016/03169A patent/ZA201603169B/en unknown
- 2016-05-20 MX MX2021006932A patent/MX2021006932A/es unknown
- 2016-05-21 SA SA516371174A patent/SA516371174B1/ar unknown
-
2018
- 2018-05-25 US US15/990,524 patent/US20190055298A1/en not_active Abandoned
-
2019
- 2019-10-17 JP JP2019190139A patent/JP6970724B2/ja not_active Expired - Fee Related
- 2019-11-28 AU AU2019272003A patent/AU2019272003B2/en not_active Ceased
-
2021
- 2021-04-15 AU AU2021202274A patent/AU2021202274A1/en not_active Abandoned
- 2021-11-01 JP JP2021178468A patent/JP2022023196A/ja active Pending
-
2022
- 2022-01-27 US US17/586,652 patent/US20220396606A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501129A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| JP2016020389A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2019508013A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| EA202090275A2 (ru) | Антитела против с5 с улучшенными фармакокинетическими характеристиками | |
| JP2016538830A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2017506217A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| JP2009535021A5 (enExample) | ||
| JP2018521983A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2019517790A5 (enExample) | ||
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| JP2014532649A5 (enExample) | ||
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ |